OXYCOTIN WILL BE WITHDRAWN FROM MARKET

Oxycontin Maker Purdue Pharma Will Stop Marketing the Drug to U.S. Doctors

Home
Subscribe

40 Under 40
100 Best Companies to Work For
Fortune 500
Global 500
50 Most Powerful Women in Business
World’s 50 Greatest Leaders
World’s Most Admired Companies
All Rankings
Automotive
Careers
Design
Energy & Environment
Executive Travel
Finance
Commentary
Health
International
Leadership
Luxury
Markets
Most Powerful Women
Retail
Sports
Technology
The Ledger
Venture
Photography
Podcasts
Newsletters
Magazine
Fortune Knowledge Group
Fortune Data Store
Fortune Conferences
TIME Health
Digital Health
Discovering Luxury
Innovation By Design
Looking Forward
MPW Mentorship
The 21st Century Corporation
Mastering the Market
Subscribe
Give a Gift
Customer Service
Stay Connected

International
Bullet Trains Are Transforming the World’s Biggest Migra…

Tech
BitGrail Cryptocurrency Exchange Claims $195 Million Los…

Entertainment
Fifty Shades Freed Leads Three New Films at Weeke…

Finance
The Equifax Hack Exposed More Data Than Previously Repor…

Health
oxycontin
Oxycontin Maker Purdue Pharma Will Stop Marketing the Drug to U.S. Doctors

Donald Trump Declares the Opioid Crisis a National Emergency
Change is coming “very, very fast.”

Pause

Mute
Current Time
2:03
/
Duration Time
2:37
Loaded: 0%

Progress: 0%

Share
Captions
Fullscreen

By David Z. Morris February 11, 2018
Purdue Pharma will no longer target U.S. doctors in its efforts to sell OxyContin, a prescription opioid whose overprescription fueled America’s opioid crisis — and made billions for Purdue’s founding family.
As reported by the Wall Street Journal, Purdue will continue selling the drug, but will no longer send salespeople to doctors’ offices to promote it. Purdue will cut its U.S. sales staff by more than half.
The move comes as opioid addiction continues to take a devastating toll on large swathes of the United States. Deaths from drug overdoses accelerated sharply in 2016 and 2017, and are now the leading cause of death among Americans under 50. Many of those overdoses are attributed to other opioids, including fentanyl and heroin, which OxyContin users often switch to after becoming addicted to the painkiller.

The boom in OxyContin prescriptions, and the resulting expansion of the deadly abuse of opioids, has been consistently blamed on Purdue’s aggressive and misleading marketing of the drug. Purdue for years made the case that OxyContin was less addictive than other opioid painkillers, and that the risks of opioid addiction in general were overblown — claims partly rooted in a decades-old anecdotal letter rather than scientific research.
In 2007, Purdue Pharma and three of its executives pleaded guilty to criminal charges of misrepresenting their product’s addictiveness, and paid a total of $635 million in fines.
Get Brainstorm Health, Fortune’s healthcare newsletter.
Purdue’s decision to entirely stop marketing the drug in the U.S. comes amid a new wave of legal action, reminiscent of the legal campaign against tobacco companies in the 1990s. States including Montana, New Jersey, and Alabama , as well as some cities, have sued Purdue, claiming that the opioid epidemic has reduced lifespans and caused massive social and economic damage. Costs of opioid addiction to the U.S. economy have been estimated to be as high as $78.5 billion.
Growing awareness of Purdue’s handling of OxyContin has also recently attracted scrutiny of the Sacklers, the family that controls the privately held firm. The Sacklers’ philanthropy has left their name prominently displayed across dozens of museums and universities, but they have carefully avoided public association with OxyContin, which reportedly generated the bulk of their wealth.

SPONSORED FINANCIAL CONTENT

You May Like

Health
The Flu is Killing Up to 4,000 Americans a Week

Health
This Company Wants to Sequence Your Genome, Put It On a Blockchain—And Pay You For It

Health
Brainstorm Health: Genome on a Blockchain, Budget Deal, U.S. Life Expectancy Drop

Health
Here’s Why Life Expectancy in the U.S. Dropped Again This Year

Health
This GV-Backed Company Thinks Its “Robotic Pill” Could Replace Painful Drug Injections

Health
Brainstorm Health: Robotic Pills, Gilead Vs Glaxo, Federal Spending Bill and Health Care

Stories From

The Next Bear Market Will Be ‘The Worst In Our Lifetime’
marketwatch.com

Judge Rules: Doctor Can’t Practice, As She Doesn’t Use A…
time.com

Jim Cramer Blames A ‘group Of Complete Morons’ For Blowi…
marketwatch.com

Whale Saves Diver From Shark, Or Did it?
valuewalk.com

President Trump’s Approval Rating Just Hit Yet Another N…
time.com

Read More

Health
The State of New Jersey Is Suing the Maker of OxyContin

Health
How the Obama Administration Is Escalating the War on Op…

Health
How One Insurer Plans to Cut Customers’ Opioid Use By 25…

Health
OxyContin’s 12-Hour Dosing Claim Attacked In Massive Inv…

Sign Up for Our Newsletters
Sign up now to receive FORTUNE’s best content, special offers, and much more.
SUBSCRIBE

Subscribe & Save
Subscribe today and save 79% off the cover price.
SUBSCRIBE NOW

Sign Up for Our Newsletters
Sign up now to receive FORTUNE’s best content, special offers, and much more.
SUBSCRIBE

40 Under 40
100 Best Companies to Work For
Fortune 500
Global 500
Most Powerful Women in Business
World’s 50 Greatest Leaders
World’s Most Admired Companies
All Rankings
Home
Automotive
Careers
Design
Energy & Environment
Executive Travel
Finance
Commentary
Health
International
Leadership
Luxury
Markets
Most Powerful Women
Retail
Sports
Technology
The Ledger
Venture
Photography
Podcasts
Videos
Newsletters
Magazine
Fortune Knowledge Group
Fortune Data Store
Fortune Conferences
TIME Health
Customer Service
Site Map
Privacy Policy
Advertising
Subscribe
Give a Gift
Ad Choices
Terms of Use
Your California Privacy Rights
Time Inc. Careers
© 2017 Time Inc. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy (Your California Privacy Rights).
Fortune may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html.
S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

About joelsnell99

Who's Who in all U.S and U.K. Honoraries (Marquis) 450 publications in 80 venues DANA SPIRIT AWARD/2009 Oxford Roundtable St.Catherine's College Editor of FOCUS, a student Social Science Journal Author Snell Life Cycle Lonliness Curve Professor Emeritus - Kirkwood College Omicron Delta Kappa $1,000,000 in grants Online Editor for Psychology and Education.com Research Fellow - Arlington Institute Fellow International Biographical Association Outstanding Teacher at Kirkwood College Membership in numerous editorial boards or a reviewer of manuscripts Associate Editor - Psychology and Education Fellow American Biographical Association Co-Author of Snell-Green Professor Index Author of Snell Educator Effectiveness Index Contributer to FutureEdition.com Co-Author of Snell-Allen Medical Rank Index Deputy Director, International Biographical Association Fellow in Kennedy Foundation Co-Author of Snell-Allen Subjective Assessment Sex Role Index Honors >>> Positions and Courses Taught >>> jsnell@kirkwood.edu jsnell@socialvibes.net snelljennifer47@hotmail.com http://www.socialvibes.net Kirkwood http://www.dana.edu Research Council, Advisory Board, International Biographical Centre
This entry was posted in New Essays. Bookmark the permalink.

Comments are closed.